173results about How to "Reduce apoptosis" patented technology

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The invention discloses a preparation method of a zinc-dihydromyricetin nano-enzyme and application of the zinc-dihydromyricetin nano-enzyme in preparation of drugs for promoting healing of diabetic wounds, and the zinc-dihydromyricetin metal polyphenol nano-enzyme (Zn-DHM) is obtained by coordinating a metal element zinc (Zn) and a natural product dihydromyricetin (DHM) through a one-step method by taking PVP as a surfactant. The Zn-DHM nano-enzyme prepared by the invention has antioxidant property and cell proliferation and migration promoting ability, and can maintain metabolism and immune homeostasis of diabetic wounds, so that the Zn-DHM nano-enzyme can accelerate early healing of the diabetic wounds.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an expression inhibitor of an NR4A1 gene in preparation of a medicine for treating wine-dependent withdrawal. It is found that after wine-dependent withdrawal, mice have anxiety behaviors, the NR4A1 level of the prefrontal lobe is increased, and apoptosis-related protein in the prefrontal lobe is increased. Knockout of the forehead NR4A1 gene intervenes the expression level of the NR4A1 gene in the forehead lobe of the mouse, it can be proved that down-regulation of the expression of the forehead lobe NR4A1 gene can rescue apoptosis and damage, caused by alcohol, of cortical neurons of the forehead lobe, relieve anxiety behaviors caused by alcohol withdrawal of the mouse, and have the effect of protecting the brain of the mouse; the inhibitor DIM-C-pPhOH of the NR4A1 protein can reduce the expression of the NR4A1 gene of the prefrontal lobe of an alcohol withdrawal mouse and anxiety-like behaviors caused by alcohol withdrawal, and provides related therapeutic targets and new therapeutic drugs for anxiety dysfunction caused by clinical alcohol dependence and alcohol dependence withdrawal.

The invention relates to the technical field of tissue isolation, and particularly discloses a high-activity intestinal crypt and an isolation method and application thereof. The separation method comprises the following steps: S1, taking fresh intestinal tracts, cleaning contents, and scraping mucous membrane layer tissues to obtain intestinal mucous membrane tissues; s2, shearing intestinal mucosa layer tissues, mixing the intestinal mucosa layer tissues with the separation liquid after cleaning, and digesting and dissociating to obtain intestinal mucosa tissue digestive juice; s3, centrifuging the intestinal mucosa tissue digestive juice, removing supernate, mixing the supernate with the protective liquid to obtain intestinal crypt mixed liquid, filtering, centrifuging, and taking precipitate to obtain high-activity intestinal crypts; wherein the separation liquid comprises collagenase I, collagenase II, collagenase IV, elastase, DNA enzyme I and a ROCK inhibitor; the protection liquid comprises an RPMI1640 culture medium, antibiotics, fetal calf serum, bovine serum albumin and a ROCK inhibitor. The technical scheme provided by the invention aims to shorten the intestinal tract crypt separation time and improve the cell viability.

The invention discloses an ADF protein from phytophthora as well as a coding gene and application thereof. According to the present invention, the PsADF protein provided by the present invention is the protein represented by sequences 2 and 5 in Phytophthora sojae (Phytophthora sojae); the coding gene is shown as a sequence 3 and a sequence 4. Tests prove that the protein provided by the invention plays an important role in the growth and development process of phytophthora sojae, specifically, after the 64-site mutation of the key amino acid functional site of the protein, the sporangium abnormality and zoospore quantity of the phytophthora sojae are reduced, and the pathogenicity is reduced. The protein provided by the invention has very high application value in control of epidemic disease occurrence and epidemic caused by phytophthora, and provides a molecular target for research and development of novel bactericides in the future. The corresponding ADF inhibitors have different degrees of activity on typical plant pathogenic oomycetes such as phytophthora sojae, phytophthora capsici and phytophthora infestans. The protein provided by the invention has great application potential in the aspect of preventing and controlling the crop epidemic diseases caused by phytophthora plant pathogenic oomycetes, and a novel bactericide developed based on the protein as an action target has important practical significance in controlling the occurrence and prevalence of the crop epidemic diseases caused by phytophthora.

The invention discloses an effect of an APOA gene in relieving vomitoxin injury of bovine liver cells by vitamin E, and relates to the technical field of the effect of vitamin E in relieving vomitoxin injury of bovine liver cells. The APOA gene refers to an APOA1 gene, an APOA2 gene and an APOA4 gene; the CDS sequence of the APOA1 gene is as shown in SEQ ID NO. 19; the CDS sequence of the APOA2 gene is as shown in SEQ ID NO. 20; the CDS sequence of the APOA4 gene is as shown in SEQ ID NO. 21; the effect is that the vitamin E regulates an APOA gene to be enriched to a cholesterol metabolic pathway. According to the effect of the APOA gene in relieving vomitoxin-caused cattle liver cells, it is found that the vitamin E can effectively protect the cell membrane integrity of the cattle liver cells and can relieve cell viability decline, oxidative stress, inflammatory response and cell apoptosis caused by vomitoxin; vitamin E regulates the cholesterol metabolic pathway by regulating the APOA gene level so as to play a role in protecting liver cells of dairy cows.

The invention relates to the technical field of biological medicines, in particular to a preparation method of extracellular vesicles derived from myocardial cells derived from human induced pluripotent stem cells as well as a product and application of the extracellular vesicles. The method comprises the following steps: pretreating human induced pluripotent stem cell derived myocardial cells (hiPSCs-CMs) by using honokiol, and culturing the treated human induced pluripotent stem cell derived myocardial cells to collect extracellular vesicles (EVs) secreted by the human induced pluripotent stem cell derived myocardial cells. The extracellular vesicles secreted by the myocardial cells derived from the human induced pluripotent stem cells pretreated by honokiol are rich in functional mitochondria, show a better myocardial infarction treatment effect in animal experiments, and have huge clinical potential.

The invention relates to the technical field of ovarian granule cell apoptosis, and discloses a method for regulating oxidative stress induced sheep ovarian granule cell apoptosis by using allicin, and the method comprises the following steps: firstly preparing a culture solution, then preparing an allicin stock solution, and identifying sheep ovarian granule cells; the method comprises the following steps: firstly, measuring the activity of ovarian granular cells after independent treatment of H2O2 and allicin, determining the optimal treatment time and concentration of H2O2 and allicin, then carrying out co-treatment of H2O2 and allicin, detecting the apoptosis of the granular cells by using flow cytometry, detecting the expression of apoptosis-related genes by using real-time fluorescent quantitative PCR, detecting the secretion of steroid hormones by using ELISA, and carrying out data analysis. The invention solves the problems that in the prior art, an effective regulation and control method for ovarian granular cell apoptosis induced by oxidative stress is lacked, and traditional medicines possibly have large side effects, unobvious effects and the like.

The invention discloses functional eye-protecting soft sweets capable of resisting oxidation and reducing apoptosis of eye cells and a preparation method. The functional eye-protecting soft sweets comprise the following components in percentage by weight: 2-10% of functional components and the balance of auxiliary materials, the functional components comprise at least one of blueberry anthocyanin, lutein ester, zeaxanthin, astaxanthin, lycopene and beta-carotene, as well as vitamin C and / or vitamin E. The functional soft sweets provided by the invention have the effects of removing DPPH free radicals and reducing eye apoptotic cells, and compared with soft sweets without vitamin C / vitamin E, the vitamin C / vitamin E added in the formula can reduce the attenuation degree of functional nutrients in the effective period.

The invention discloses application of plasmalogen in preparation of a medicine for promoting spinal cord injury repair. The invention further discloses application of the plasmalogen in preparation of drugs for regulating neuroinflammation or oxidative stress in spinal cord injury. The invention also discloses application of the plasmalogen in preparation of a medicine for promoting motor function recovery after spinal cord injury. The invention further discloses application of the plasmalogen in preparation of a medicine for neuroprotection in spinal cord injury. The invention further discloses application of the plasmalogen to preparation of a medicine for nerve cell myelin sheath regeneration after spinal cord injury. The invention also discloses application of the plasmalogen in preparation of a medicine for promoting nerve fiber regeneration after spinal cord injury. It is found that plasmalogen can effectively reduce the ROS level and regulate and control neuroinflammation and oxidative stress levels, so that neuronal axis mutability and apoptosis are reduced, and neuronal myelin regeneration is promoted.

The invention relates to the technical field of biology, in particular to a matrix-enabled mesenchymal stem cell aggregate and application, and the matrix-enabled mesenchymal stem cell aggregate is obtained by subculturing matrix-enabled mesenchymal stem cells in a 3D cell culture system. The matrix-enabled mesenchymal stem cells are obtained by subculture of mesenchymal stem cells in a cell culture matrix, and the cell culture matrix is prepared from 1-3 parts of hE-cad-Fc and 1-3 parts of hN-cad-Fc. Endogenous epithelium cadherin and nerve cadherin are highly expressed in cell aggregation cells, so that transcription factors are promoted to enter nuclei, the expression levels of anti-inflammatory immune regulation related factors and matrix degradation and cell migration related factors are up-regulated, and activated macrophages are promoted to be polarized to M2 type macrophages; the effects of anti-inflammation, immune regulation, tissue damage repair and the like of intravenous implantation of the matrix-enabled mesenchymal stem cell aggregate for treating diseases such as hepatic fibrosis, diabetes mellitus, nerve injury and the like are remarkably improved.

The invention relates to application of thyroid hormone T3 in preparation of a medicine for delaying or treating intervertebral disc degeneration, and the thyroid hormone T3 can inhibit glycolysis capability of degeneration nucleus pulposus cells and reduce intervertebral disc lactic acid accumulation, so that nucleus pulposus cell senescence and apoptosis are relieved, and intervertebral disc degeneration is delayed or treated. Compared with the prior art, the technology for delaying or treating intervertebral disc degeneration by applying the thyroid hormone T3 provides new application of the thyroid hormone T3, the application value of the thyroid hormone T3 is greatly improved, the application range of the thyroid hormone T3 is expanded, the new field of application of the thyroid hormone T3 is expanded, and the thyroid hormone T3 has wide application prospects and commercial value.

The invention discloses application of sulfhydrylated hyaluronic acid or salt thereof in myocardial ischemia-reperfusion injury, and belongs to the technical field of biomedical treatment. In the application, the substitution degree of sulfydryl of the synthesized sulfhydrylated hyaluronic acid or salt thereof can reach 10-40%. The oxidation resistance of 5mg / ml of sulfhydrylated hyaluronic acid or salt thereof can reach more than 50%; in the SI / RI model of the H9C2 myocardial cells, the HA-SH can protect the H9C2 myocardial cells, and meanwhile, the oxidative stress injury in the SI / RI model can be remarkably reduced; in a constructed rat myocardial ischemia reperfusion injury model, HA-SH can relieve oxidative stress injury, cell apoptosis and inflammatory response caused by myocardial ischemia reperfusion by regulating and controlling an Nrf2 signal channel and an HO-1 signal channel, reduce the iron death rate and play a role in protecting the heart. The invention provides a new drug research and development approach, and has important significance in the technical field of biomedical treatment.

The invention belongs to the technical field of biological medicines, and discloses application of Weissella cibaria ZMC030 and exopolysaccharides thereof in prevention and treatment of colitis. The preservation number of the Weissella sinus ZMC030 is CCTCC (China Center for Type Culture Collection) NO: M 20241261, and the Weissella sinus ZMC030 is preserved in the China Center for Type Culture Collection. The Weissella cibaria ZMC030 can secrete exopolysaccharide, and the secreted exopolysaccharide can relieve intestinal injury, reduce apoptosis of intestinal epithelial cells, effectively protect intestinal mucosa barriers and reduce the inflammation level; moreover, intestinal microorganisms and metabolites thereof can be regulated and controlled, the level of pro-inflammatory microorganisms is reduced, the level of anti-inflammatory microorganisms and short-chain fatty acid is increased, and ulcerative colitis symptoms of mice are finally relieved; in addition, the exopolysaccharide has no influence on the weight and the growth state of the mouse, has no damage to important visceral organs, and is high in safety. Therefore, the Weissella cibaria ZMC030 and the exopolysaccharide secreted by the Weissella cibaria ZMC030 can be used for preparing the medicine for relieving or / and treating the colitis.

The invention discloses application of liver-soothing and kidney-tonifying conceptive decoction in preparation of a medicine for treating hypothyroidism type asthenospermia. The liver-soothing and kidney-tonifying conceptive decoction is prepared from 12-18 g of tribulus terrestris, 12-18 g of radix curcumae, 12-18 g of fructus lycii, 12-18 g of semen cuscutae, 12-18 g of ligusticum wallichii, 8-12 g of deer-horn glue (molten), 8-12 g of raspberry, 8-12 g of flatstem milkvetch seed and 8-12 g of schisandra chinensis. The liver soothing and kidney tonifying conceptive decoction can repair testis oxidative stress injury, recover thyroid hormone level, regulate endoplasmic reticulum stress PERK / EIF2alpha / ATF4 signal channels and down-regulate pro-apoptotic protein CHOP expression level, so that spermatogenic cell apoptosis is relieved, and a new way is provided for preparation and development of drugs for treating male asthenospermia caused by hypothyroidism.

The invention relates to the technical field of tissue preservation, in particular to tissue preservation liquid for organoid culture as well as a preparation method and application of the tissue preservation liquid. The tissue preserving fluid provided by the invention takes an Advanced DMEM / F12 culture medium as a basic culture medium, and comprises the following components in concentration: 50-60 [mu] M of 2-mercaptoethanol, 10-30 g / L of bovine serum albumin, 100-200 [mu] g / ml of a primary cell antibiotic and 8-12 [mu] M of a ROCK inhibitor. By compounding the components with proper concentrations, the obtained tissue preserving fluid can preserve a tissue sample for organoid culture at low temperature for 72 hours, maintain tissue cell activity and reduce cell damage, does not influence organoid culture, and improves the organoid culture success rate.

The invention relates to the technical field of psychiatric pharmacology, discloses application of helicid in antidepressant drugs, and aims to solve the problems of large side effect, unstable curative effect, drug resistance and the like of existing antidepressant drugs. According to the medicine, through multiple mechanisms of activating a cAMP / PKA / CREB signal channel, promoting neuroplasticity, inhibiting neuronal apoptosis, relieving neuroinflammation and the like, the depressive symptom is remarkably improved. The preparation method comprises the steps of extraction and purification of helicid and preparation of the medicinal preparation. Animal experiments verify that the hilicidum-based antidepressant drug can effectively improve behavioral indexes of depression model rats, has low side effects, and does not have the problem of drug resistance. Compared with the traditional medicine, the medicine provided by the invention has the advantages that the treatment effect is improved, the adverse reaction is reduced, the application prospect is better, and a new medicine choice with a multi-target action mechanism is provided for the treatment of depression.

The invention provides a method for relieving intestinal barrier injury caused by fluorine overexposure by using tea polyphenol. The method for relieving intestinal barrier injury caused by fluorine overexposure by using tea polyphenol comprises the following steps: carrying out an in-vitro test on porcine jejunum epithelial cells (IPEC-J2 cells) and establishing a NaF induction model by using the IPEC-J2 cells, and specifically comprises the following steps: S1, preparing test materials: the IPEC-J2 cells, a DMEM culture medium, a sterile phosphate buffer solution, fetal calf serum, mycillin and a cell freezing medium; s2, carrying out cell resuscitation, and establishing a NaF-induced cell model. The method for relieving intestinal barrier injury caused by fluorine overexposure by tea polyphenol has the advantages that the integrity of the intestinal barrier is increased and the intestinal microecology is repaired by increasing the activity of antioxidant enzyme, reducing the permeability of the intestinal tract, reducing the production of reactive oxygen species (ROS) and relieving oxidative stress and intestinal cell apoptosis caused by NaF.

This invention discloses a method for preparing HVC NPs for the diagnosis and treatment of Parkinson's disease and their applications. The probe HV in the HVC NPs responds to H2O2 and viscosity, utilizing near-infrared fluorescence imaging capabilities to achieve real-time monitoring of Parkinson's disease biomarkers, helping us better understand the occurrence and development of Parkinson's disease. With the assistance of RVG29, the HVC NPs effectively cross the blood-brain barrier. The curcumin within them can reduce cell apoptosis, lower oxidative stress levels, scavenge excess reactive oxygen species, combat inflammation, and reduce α-synuclein aggregation, demonstrating effective anti-Parkinson's disease effects at the cellular and experimental animal levels. This nanomaterial provides a new strategy for integrated research on the diagnosis and treatment of Parkinson's disease.

The invention provides an inhibitor in a diabetic nephropathy drug, application of the inhibitor and the drug, and belongs to the field of pharmaceutical preparations, the inhibitor is an HDAC8 inhibitor, and administration of the HDAC8 inhibitor improves pathological structure changes of renal tubules caused by diabetes and inhibits the fibrosis process of the renal tubules at the same time; glycogen deposition is improved to a certain degree after administration, then renal tubular epithelial cell apoptosis is relieved, the treatment effect is achieved, and a new medicine and a new treatment mode are provided for treatment of diabetic nephropathy.

This invention belongs to the field of medical technology, specifically relating to the application of mitochondrial transplantation to regulate the immune-metabolic network in the treatment of myocardial dysfunction after cardiac arrest. The mitochondrial transplantation is performed within 0.5-2 hours after the restoration of spontaneous cardiac circulation. This technical solution, through multi-omics integrated analysis, proposes that mitochondrial transplantation exerts a cardioprotective effect by regulating the immune-metabolic-mitochondrial triaxial synergistic network, providing a new research direction for the precision treatment of myocardial dysfunction after cardiac arrest.

The invention discloses a nutritional supplement as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The invention provides a nutritional supplement capable of maintaining and even improving the cell viability at the later stage of cell culture. The nutritional supplement comprises the following components in parts by weight: 0.05-0.6 part of choline chloride, 0.1-0.6 part of lithium chloride and 0.1-0.2 part of taurine. By compounding the taurine, the lithium chloride and the choline chloride, the invention provides the nutritional supplement capable of maintaining and even improving the cell viability in the later period of cell culture.

This invention relates to the field of cell biology, specifically to a co-culture cell model and method for primary glial cells and neurons. The method for co-culturing primary glial cells and neurons provided by this invention includes the following steps: a mixture of primary glial cells and neurons is seeded into a first co-culture medium for pre-culture; the medium is discarded and the cells are washed; a second co-culture medium is added for a first-stage culture; after the first-stage culture, a second-stage culture is performed; the medium used in the second-stage culture is a third co-culture medium supplemented with macrophage colony-stimulating factor; after the second-stage culture, a third-stage culture is performed; the medium used in the third-stage culture is the second co-culture medium; in the obtained co-culture cell model, microglia are differentiated and mature, and are in a quiescent state, thus obtaining a primary glial cell and neuron co-culture model.

The application provides application of a CSRNP1 inhibitor in preparation of a medicine for treating liver ischemia-reperfusion injury. The application further clarifies a molecular mechanism in which CSRNP1 improves hepatocyte injury by targeting a MAPK signaling pathway mediated cell apoptosis in the process of ischemia-reperfusion, and provides a new treatment strategy for reducing ischemia-reperfusion injury in a liver surgery process, by deeply analyzing expression changes of CSRNP1 in the process of liver ischemia-reperfusion and correlation between the expression changes and ischemia-reperfusion injury caused by a liver surgery.

The invention relates to the field of A61K8 / 00, in particular to a composition for promoting rapid growth of hair and application of the composition. By adopting the specific amino acid composition, the physiological active component, the plant source glucoside, the protein hydrolysate, the diguanide tetraphosphate and the anti-inflammatory agent, through the synergistic effect of all the active raw materials, the provided composition for promoting rapid growth of hair is added to prepare hair washing and hair care products, and the hair washing and hair care products are applied to people with alopecia to use or treat the alopecia. Hair stem cell stimulation and rapid hair follicle regeneration are effectively induced, scalp aging is prevented, the treatment effect is remarkable, and no obvious side effect exists.

The invention belongs to the field of medicines, and discloses application of notoginsenoside R1 (NgR1) in preparation of a medicine for treating chemotherapy-induced peripheral neuropathy. The NgR1 can significantly increase the mechanical pain threshold of chemotherapy pain, reduce inflammatory cell infiltration in dorsal root ganglions and expression of inflammatory factors such as IL-6, TNF-alpha and IL-1beta, also can significantly improve microcirculation disturbance, reduce expression of CGRP and c-fos in spinal cords, reduce expression of Cleved caspase 3 (a marker of cell apoptosis) in the dorsal root ganglions, and significantly improve chemotherapy pain. Therefore, the chemotherapy-induced peripheral neuropathy is relieved in a multi-target manner. The NgR1 treats the CIPN through three ways of relieving inflammatory response, improving microcirculation disturbance and inhibiting neuronal apoptosis, the safe and effective treatment purpose is achieved, and a new strategy is provided for clinical treatment of the CIPN.

The invention discloses a retinoid composition capable of reducing irritation and resisting aging and application thereof, and belongs to the technical field of preparations for dressing and makeup. The irritation-reducing and anti-aging retinoid composition comprises an anti-aging component and ginsenoside CK, the anti-aging component comprises at least one of retinol and a retinol derivative, and the mass ratio of the anti-aging component to the ginsenoside CK is 1: (0.001-2). The retinoid composition disclosed by the invention has the effects of being small in irritation and synergistically promoting aging resistance. According to the invention, the verbascos exosome is further compounded with a retinoid composition, and the retinoid composition enters the exosome through ultrasonic treatment and incubation so as to enable vesicles to wrap the composition, so that the activity of the composition can be protected, the irritation is further reduced, and the anti-aging effect is improved. Therefore, the retinoid composition provided by the invention is suitable for daily cosmetics.

The application discloses a normal-temperature extracorporeal perfusion solution for maintaining liver activity, and mainly relates to the technical field of organ perfusion. The normal-temperature extracorporeal perfusion solution for maintaining liver activity comprises the following components: high-efficiency oxygen-carrying carriers HBOC, energy metabolism components, hormones and growth factors, antioxidant components, microcirculation protection factors, HEPES buffer, inorganic salts, amino acids and vitamins. Compared with the prior art, the perfusion solution can make an isolated liver maintain a high bile secretion amount and stable portal vein pressure during normal-temperature perfusion, reduce the rising range of ALT and AST, reduce hepatocyte apoptosis and protect the structural integrity of mitochondria, thereby effectively reducing hepatocyte damage, maintaining liver activity, and being suitable for isolated liver preservation, pre-transplantation evaluation and related extracorporeal experiments.

This invention belongs to the field of microbial application technology, specifically relating to a method for preparing fermented *Lactobacillus limnoxicamis* extracellular vesicles, the product, and its applications, particularly the application of these fermented *Lactobacillus limnoxicamis* extracellular vesicles and their lyophilized formulations in the preparation of products with antioxidant or anti-aging effects. In this invention, *Lactobacillus limnoxicamis* is inoculated into a modified extracellular vesicle induction medium for fermentation. After culture, a two-stage solid-liquid separation is performed, and the supernatant is collected to obtain the extracellular vesicle processing solution. This solution is purified using a capillary electrophoresis system, and the positive extreme liquid is collected and filtered to obtain the purified product of fermented *Lactobacillus limnoxicamis* extracellular vesicles. The extracellular vesicles derived from fermented *Lactobacillus limnoxicamis* prepared by this invention can effectively scavenge free radicals. Somatic cell experiments have demonstrated its excellent anti-aging properties, and the transformation and application research of *Lactobacillus* extracellular vesicles has explored its development potential in the field of anti-aging products.

The invention belongs to the technical field of preparation methods of collagen peptides, and particularly relates to a preparation method of a collagen peptide for improving facial skin, fish tissues are used as raw materials, and the preparation method comprises the steps of picking and washing, cooking, two-step enzymolysis, filtration, primary ultrafiltration, glycosylation reaction, secondary ultrafiltration, concentration, sterilization, spray drying and sieving. The glycosylation reaction involved in the invention comprises a process of performing glycosylation on a fish collagen peptide crude product by using plant polysaccharide and disaccharide. The collagen peptide prepared by the preparation method disclosed by the invention not only has good oxidation resistance, but also has good water absorption and moisturizing properties, so that the facial skin can be effectively improved.